Cargando…

Assessment of the vaccine industry in Iran in context of accession to WTO: a survey study

BACKGROUND: The vaccine industry is one of the most important health-related industries. It can be affected by accession to the World Trade Organization (WTO) because of probable dramatic changes in the business environment. Iran has already initiated accession negotiations. PURPOSE OF THE STUDY: In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hashemi Meshkini, Amir, Kebriaeezadeh, Abbas, Dinarvand, Rasoul, Nikfar, Shekoufeh, Habibzadeh, MohammadGafar, Vazirian, Iman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555710/ https://www.ncbi.nlm.nih.gov/pubmed/23351841 http://dx.doi.org/10.1186/2008-2231-20-19

Ejemplares similares

Pharmacists Remuneration Models in Iran and Selected Countries: a Comparative Study
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business?
por: Keshavarz, Khosro, et al.
Publicado: (2012)

A model for developing a decision support system to simulate national drug policy indicators
por: Abdollahiasl, Akbar, et al.
Publicado: (2011)

Pharmaceutical laws and regulations in Iran: An overview
por: Zaboli, Pardis, et al.
Publicado: (2016)

A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience
por: Keshavarz, Khosro, et al.
Publicado: (2013)

Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran
por: Aajami, Zahra, et al.
Publicado: (2019)

From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2014)

A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model
por: Keshavarz, Khosro, et al.
Publicado: (2016)

Evaluation of COVID-19 Treatments in Iran in Comparison with Local Therapeutic Recommendations: A Population-Level Study on Utilization and Costs of Prescription Drugs
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2022)

Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran
por: Nikfar, Shekoufeh, et al.
Publicado: (2005)

Consistent defined threshold and equity in health
por: Nikfar, Shekoufeh, et al.
Publicado: (2015)

Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries
por: Kebriaeezadeh, Abbas, et al.
Publicado: (2013)

Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2023)

A system dynamics model for national drug policy
por: Abdollahiasl, Akbar, et al.
Publicado: (2014)

Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran
por: Teimouri, Fatemeh, et al.
Publicado: (2017)

WTO accession and firm exports in developing economies
por: Nuruzzaman, N., et al.
Publicado: (2021)

Commercialization of biopharmaceutical knowledge in Iran; challenges and solutions
por: Nassiri-Koopaei, Nasser, et al.
Publicado: (2014)

Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies
por: Rezvanfar, Mohammad Ali, et al.
Publicado: (2013)

Making the Public Health and Industrial Objectives Balanced; the Big Challenge of Iran’s Food and Drug Organization
por: HASHEMI-MESHKINI, Amir
Publicado: (2014)

Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran
por: HAYATI, Hadi, et al.
Publicado: (2018)

Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children
por: Gharibnaseri, Zahra, et al.
Publicado: (2012)

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2018)

Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
por: Keshavarz, Khosro, et al.
Publicado: (2015)

Is Taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost- effectiveness analysis
por: Kavosi, Zahra, et al.
Publicado: (2016)

Resource allocation and purchasing arrangements to improve accessibility of medicines: Evidence from Iran
por: Bastani, Peivand, et al.
Publicado: (2015)

Pharmaceutical supply chain risks: a systematic review
por: Jaberidoost, Mona, et al.
Publicado: (2013)

China’s Accession to the WTO as a Shock to Residents’ Health—A Difference-in-Difference Approach
por: Sun, Yiping, et al.
Publicado: (2022)

A Scoping Review of Different Methods of Assessing the Impact of New Medical Technologies at Early Stages of Development
por: Goudarzi, Zahra, et al.
Publicado: (2021)

Social accounting matrix and the effects of economic reform on health price index and household expenditures: Evidence from Iran
por: Keshavarz, Khosro, et al.
Publicado: (2017)

The Applicability of the Law of the WTO to Green Energy Security
por: Rutherford, Angelica
Publicado: (2020)

“Annual Pharma Statistics” as a Health Information System Application in Iranian Pharmaceutical Sector
por: Farshchi, Amir, et al.
Publicado: (2015)

Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials
por: Keshavarz, Khosro, et al.
Publicado: (2017)

Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective
por: Ahmadiani, Saeed, et al.
Publicado: (2016)

A review on inputs and outputs in determining the efficiency of universities of medical sciences by data envelopment analysis method
por: Mojahedian, Mohammad M., et al.
Publicado: (2020)

A Systematic Review of Discrete Choice Experiment Studies in Rheumatoid Arthritis Biological Medicines
por: Zartab, Saman, et al.
Publicado: (2021)

Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders
por: Kohler, Jillian, et al.
Publicado: (2022)

The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access
por: Esmail, Laura C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nscchhat7pqirpnmtpmhk618e1